A pyrimethanil-ferulic acid eutectic, its preparation method and application

By preparing pyrimethanil-ferulic acid cocrystals, a stable supramolecular cocrystal structure is formed through hydrogen bonding and π-π stacking interactions, which solves the problems of volatility and photodegradation of pyrimethanil, improves its thermal stability and resistance to photolysis, and realizes the controllable release and efficient utilization of active ingredients.

CN123106554APending Publication Date: 2026-11-17TIANJIN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611130288.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-28
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Pyrimethanil, as a fungicide, has problems such as high volatility and easy photodegradation in practical applications, which leads to a decrease in effective utilization and an increase in environmental risks. Furthermore, long-term low-concentration residues may accelerate the development of drug resistance in pathogens.

Method used

By forming a pyrimethanil-ferulic acid eutectic, a stable supramolecular eutectic structure is formed by utilizing the hydrogen bonds and π-π stacking interactions between pyrimethanil and ferulic acid. Pyrimethanil is locked in the crystal lattice, and ferulic acid provides a photon shielding layer to block the damage of ultraviolet light.

Benefits of technology

It significantly improves the thermal stability and resistance to photodegradation of pyrimethanil, reduces volatilization loss, prolongs the duration of efficacy, and achieves controlled release of active ingredients, making it suitable for rapid-acting disease control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106554A_ABST
    Figure CN123106554A_ABST
Patent Text Reader

Abstract

This invention discloses a pyrimethanil-ferulic acid co-crystal, its preparation method, and its applications. The pyrimethanil-ferulic acid co-crystal is formed by the non-covalent self-assembly of pyrimethanil and ferulic acid in a molar ratio of 1:0.5. Pyrimethanil and ferulic acid co-assemble into supramolecular nano-co-crystals through non-covalent interactions at a predetermined stoichiometric ratio. This invention effectively overcomes the defects of high volatility and easy photodegradation of traditional agricultural active ingredients. The volatility inhibition rate of the pyrimethanil co-crystal reaches over 80%, and its resistance to photodegradation in both liquid and solid phases is significantly improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the interdisciplinary fields of agricultural chemistry, crystal engineering and nanomaterials, specifically to a pyrimethanil-ferulic acid eutectic, its preparation method and application. Background Technology

[0002] Plant pathogenic fungal diseases pose a significant threat to global agricultural production. Among them, gray mold, caused by *Botrytis cinerea*, is characterized by its wide host range, rapid spread, and strong environmental adaptability, severely impacting the yield and quality of fruits, vegetables, cash crops, and food crops. Pyrimethanil, an aniline pyrimidine fungicide, possesses excellent systemic conductivity and broad-spectrum, high-efficiency fungicidal activity, and has been widely used for the control of fungal diseases such as gray mold. However, pyrimethanil still has significant physicochemical defects in practical applications. It has a high saturated vapor pressure (2.2 mPa, 25℃), making it prone to volatilization loss; it is also sensitive to light, easily undergoing photodegradation, leading to reduced effective utilization. Its high volatility not only causes substantial loss of the active pesticide ingredient during application, but the volatilized active molecules can also migrate into non-target areas with the air, posing potential risks to the surrounding ecological environment and operators. Furthermore, long-term low-concentration residues in the farmland environment may accelerate the development and evolution of pathogen resistance.

[0003] Therefore, how to improve the volatility of pyrimethanil, enhance its environmental stability, and achieve controlled release and efficient utilization has become a key technical problem that urgently needs to be solved in the field of pesticide formulation. Summary of the Invention

[0004] The purpose of this invention is to provide a pyrimethanil-ferulic acid eutectic, its preparation method, and its application.

[0005] To achieve the above-mentioned objectives, the present invention adopts the following technical solution: One of the objectives of this invention is to provide a pyrimethanil-ferulic acid eutectic, wherein the pyrimethanil-ferulic acid eutectic is formed by the non-covalent self-assembly of pyrimethanil and ferulic acid in a molar ratio of 1:0.5.

[0006] In this application, hydrogen bonds (NH···O, OH···N, etc.) can be formed between the pyrimidine nitrogen atom on the pyrimidine molecule and the carboxyl group and phenolic hydroxyl group on the ferulic acid molecule. At the same time, π-π stacking interactions may also exist between the aromatic rings of the two. When the molar ratio is 2:1 (i.e., pyrimidine:ferulic acid = 1:0.5), two pyrimidine molecules and one ferulic acid molecule assemble into a thermodynamically stable supramolecular eutectic structure through the above-mentioned non-covalent interactions.

[0007] In this application, the pyrimethanil-ferulic acid co-crystal, with its dense hydrogen bond network, locks pyrimethanil in a stable lattice, thereby significantly improving thermal stability; the ferulic acid constructs a natural "photon shielding layer" within the co-crystal lattice, effectively blocking the damage of ultraviolet light, increasing the anti-photodegradation half-life of pyrimethanil, and thus greatly reducing the efficacy decay under strong light.

[0008] In this application, ferulic acid is a natural phenolic acid compound widely found in plant cell walls, exhibiting good biocompatibility and certain natural antibacterial activity. Its molecular structure simultaneously contains carboxyl, phenolic hydroxyl, and conjugated aromatic structures, enabling it to participate in supramolecular assembly as both a hydrogen bond donor and acceptor, and also possessing certain light absorption and antioxidant capabilities. Utilizing ferulic acid as a functional ligand holds promise not only for reducing the volatility and photodegradation rate of pyrimethanil through intermolecular interactions, but also for potentially endowing the system with synergistic antibacterial and environmentally friendly properties.

[0009] Preferably, the single-crystal structure of the pyrimethanil-ferulic acid eutectic belongs to the triclinic crystal system, with space group P- The unit cell parameters are: a = 8.8200 Å, b = 10.7979 Å, c = 17.0715 Å, α = 79.903°, β = 76.930°, γ = 84.617°.

[0010] In this application, the arrangement of the pyrimethanil-ferulic acid eutectic in three-dimensional space was determined by single-crystal diffraction. The single-crystal structure shows that there is no high symmetry inside the crystal, and the intermolecular hydrogen bond network and stacking mode are unique.

[0011] Preferably, the X-ray powder diffraction pattern of the pyrimethanil-ferulic acid eutectic measured by Cu-Kα radiation has characteristic diffraction peaks at 2θ of 8.140°, 8.840°, 16.350°, 17.850°, and 25.630°, with an error range of ±0.2°.

[0012] Preferably, the average particle size of the pyrimethanil-ferulic acid eutectic is 10-1000 nm, more preferably 300-700 nm.

[0013] In this application, the pyrimethanil-ferulic acid co-crystal is a supramolecular nano-co-crystal. By regulating the molecular interaction mode between pyrimethanil and ferulic acid, the co-crystal can be constructed in a controllable manner, thereby forming a stable nanoscale delivery platform to improve the volatility, photostability and drug release rate of pyrimethanil, thereby enhancing its utilization efficiency and disease control effect.

[0014] A second objective of this invention is to provide a method for preparing the pyrimethanil-ferulic acid cocrystal as described in one objective, the method comprising: Pyrimethanil and ferulic acid were mixed in a molar ratio of 1:(0.45-0.5) and ball-milled to obtain a pyrimethanil-ferulic acid eutectic.

[0015] In this application, the molecular interaction mode of pyrimethanil and ferulic acid is controlled by adjusting the molar ratio of pyrimethanil and performing ball milling, thereby achieving the controllable construction of the cocrystal. When the molar ratio of pyrimethanil to ferulic acid is higher than 1:(0.45-0.5), the product obtained is a combination of pyrimethanil and pyrimethanil-ferulic acid cocrystal, which leads to waste of raw materials and also raises issues for subsequent separation. When the molar ratio of pyrimethanil to ferulic acid is lower than 1:(0.45-0.5), the pyrimethanil-ferulic acid cocrystal cannot be obtained.

[0016] Preferably, the ball milling is carried out in a ball milling medium and a mixed solution; Preferably, the ball milling media comprises zirconium oxide with an average particle size of 0.1-1 mm; Preferably, the mixed solution is an aqueous solution containing a dispersant and a wetting agent; Preferably, the dispersant comprises sodium lignosulfonate, Atlox 4913, Atlox 4917, and Atlox Metasperse 500L, and the mass fraction of the dispersant in the mixed solution is 1%-5%. Preferably, the wetting agent includes sodium dodecylbenzenesulfonate, sodium dodecyl sulfate, Tween 20, Tween 80, and Atlas G-5002L, and the mass fraction of the wetting agent in the mixed solution is 1%-5%.

[0017] In this application, ball milling is carried out in a grinding medium (preferably 0.1-1 mm zirconia beads) and an aqueous solution containing dispersants and wetting agents. The wet milling process has high yield and low dust, and the additives prevent nanoparticle agglomeration and reduce surface tension.

[0018] Preferably, the ball mill is a planetary ball mill; Preferably, the ball milling rate is 300-600 rpm and the ball milling time is 30-90 min.

[0019] Preferably, the preparation method further includes sequentially performing solid-liquid separation, washing, and freeze-drying on the mixture obtained after ball milling; Preferably, the solid-liquid separation method is filtration; Preferably, the cleaning process involves rinsing with deionized water 3-5 times. Preferably, the drying temperature is -50°C and the drying time is 24-48 hours.

[0020] A third objective of this invention is to provide a pesticide formulation comprising the pyrimethanil-ferulic acid cocrystal described in one objective.

[0021] In this application, the pesticide formulation also includes agriculturally acceptable carriers, surfactants, and other excipients.

[0022] In this application, the types of pesticide formulations include suspension concentrates, water-dispersible granules, etc.

[0023] The fourth objective of this invention is to provide a pyrimethanil-ferulic acid cocrystal as described in the first objective, or a pesticide formulation as described in the third objective, for use in the prevention and control of agricultural diseases or in the preparation of controlled-release formulations.

[0024] Preferably, the agricultural disease is a fungal disease caused by gray mold, black spot, leaf mold or brown spot.

[0025] Compared with the prior art, the present invention has the following beneficial effects: (1) Significantly improved thermal stability: By combining highly volatile pyrimethanil with ferulic acid through intermolecular non-covalent bonds to form a stable eutectic lattice, pyrimethanil is effectively locked in a stable lattice, with a 12-hour volatilization inhibition rate of over 80% (eutectic), which significantly reduces the loss of effective ingredients and environmental risks during application.

[0026] (2) Excellent resistance to photodegradation: The co-crystal ligand ferulic acid has natural ultraviolet absorption capacity, and its orderly arrangement in the co-crystal lattice constructs a "photon shielding layer" for pyrimethanil molecules. Whether in liquid or solid state, the co-crystal of the present invention significantly enhances the resistance to photodegradation of pyrimethanil, and its photodegradation half-life can be extended to more than 2 times (liquid phase) and more than 1.4 times (solid phase) of the original drug, effectively prolonging the duration of drug efficacy.

[0027] (3) Adjustable release behavior: The co-crystal form endows the active ingredient with unique release kinetics. The pyrimethanil-ferulic acid co-crystal of this application exhibits a faster release rate than the original drug, which makes it suitable for disease control scenarios that require rapid onset of action.

[0028] (4) Simple preparation process: This application adopts a high-efficiency and green wet-assisted ball milling process, which can complete the formation and nano-sizing of eutectic in one step. It is simple to operate and easy to industrialize. Attached Figure Description

[0029] Figure 1 The image shows the X-ray powder diffraction (PXRD) pattern of the pyrimethanil-ferulic acid eutectic prepared in Example 1.

[0030] Figure 2The diagram shows the minimum asymmetric unit structure of the single crystal structure of the pyrimethanil-ferulic acid eutectic prepared in Example 1.

[0031] Figure 3 The image shows a scanning electron microscope (SEM) image of the pyrimethanil-ferulic acid eutectic prepared in Example 1.

[0032] Figure 4 The particle size distribution diagram is shown for the pyrimethanil-ferulic acid eutectic prepared in Example 1.

[0033] Figure 5 The image shows the differential scanning calorimetry (DSC) curve of the pyrimethanil-ferulic acid eutectic prepared in Example 1.

[0034] Figure 6 This is a comparison of the 12-hour volatility of the pyrimethanil-ferulic acid eutectic prepared in Example 1 and the pyrimethanil technical grade.

[0035] Figure 7 This is a comparison of the photodegradation curves of the aqueous solution of pyrimethanil-ferulic acid eutectic prepared in Example 1 and pyrimethanil technical.

[0036] Figure 8 This is a comparison of the solid-state photodegradation curves of the pyrimethanil-ferulic acid eutectic prepared in Example 1 and the pyrimethanil technical grade.

[0037] Figure 9 This is a comparison of the in vitro release curves of the pyrimethanil-ferulic acid cocrystal prepared in Example 1 and the technical grade pyrimethanil. Detailed Implementation

[0038] The technical solution of the present invention will be further illustrated below through specific embodiments. Those skilled in the art should understand that the embodiments described are merely illustrative of the present invention and should not be construed as limiting the invention.

[0039] The following analytical methods and equipment were used to characterize and test the pyrimethanil-ferulic acid cocrystal of the present invention: X-ray powder diffraction (PXRD): The test was conducted using a MiniFlex600 X-ray powder diffractometer manufactured by Rigaku Corporation of Japan, with Cu Kα as the radiation source (wavelength λ=1.5406 Å), voltage 40 kV, current 15 mA, continuous scanning mode, and scanning speed of 10° / min. The test data were analyzed and processed by Jade 7.0 software to characterize the crystal structure of the sample.

[0040] Differential Scanning Calorimetry (DSC): A Mettler Toledo DSC 1 / 500 instrument was used for testing. Approximately 10 mg of sample was added to a 40 μL standard aluminum crucible, which was then sealed and placed in the furnace. High-purity nitrogen was used as the protective gas (gas rate 50 mL / min) and the reaction gas (gas rate 200 mL / min) inside the furnace. The heating rate was 10 °C / min. The temperature and heat changes of the sample during heating were measured. Program control, data recording, and analysis were all performed using STARe Software 10.0 developed by Mettler Toledo.

[0041] Thermogravimetric analysis (TG): A Mettler Toledo TGA / DSC3+ instrument was used for testing. Approximately 10 mg of sample was added to a 70 μL standard aluminum crucible, which was then placed in the heating furnace chamber. High-purity nitrogen was used as a protective gas in the furnace chamber (gas rate of 20 mL / min), and the heating rate was 10 °C / min. The weight change of the sample during heating was measured. Program control, data recording, and analysis were all completed using STARe Software 10.0 developed by Mettler Toledo.

[0042] Scanning Electron Microscope (SEM): The instrument is a Thermo Fisher Scientific Apreo S LoVac field emission scanning electron microscope, equipped with a Bruker XFlash 6|60 energy dispersive spectrometer and a Cressington 108 ion sputtering system. It features low vacuum (LoVac), immersion, and electrostatic modes, enabling sub-nanometer resolution morphology observation and elemental composition analysis.

[0043] Product particle size distribution analysis: Microscopic morphology images of samples were taken using SEM, and particle size statistical analysis was performed using ImageJ software: ImageJ size calibration was completed using the built-in ruler of the SEM images; the diameter of well-dispersed particles was measured, and the number of particles in each sample group was ≥200; after exporting the data, a particle size distribution histogram was plotted using Origin, and the average particle size was calculated.

[0044] Volatility Test: The volatility of pyrimethanil and pyrimethanil-ferulic acid eutectic was tested according to the method previously reported by Tang et al. (J.Agric. Food Chem., 2019, 67(40): 11018-11024.) with slight adjustments. Approximately 0.1500 g of PYR or multi-component sample was weighed using an analytical balance and the powder was evenly distributed in a petri dish (7 cm in diameter). The petri dish was then placed in a constant temperature oven at 75 °C, and the sample mass was re-weighed every 3 hours for a total test time of 12 hours. Volatility was defined as weight loss (mg) within a specific time period (hour). All treatments were repeated 3 times in the experiment.

[0045] Photocatalytic degradation test: The photocatalytic degradation performance of pyrimethanil and pyrimethanil-ferulic acid cocrystal in solution was evaluated using a 40W ultraviolet low-pressure mercury lamp with a wavelength of 254 nm. A 10 mg / L solution was prepared with water, and 30 mL of sample was accurately measured and placed in a quartz glass tube. The glass tube was fixed 12 cm away from the ultraviolet lamp for illumination. At predetermined time intervals, 0.5 mL of solution was accurately transferred, filtered through a 0.22 μm filter membrane, and analyzed by high-performance liquid chromatography (HPLC, Waters 2996).

[0046] Solid-state photolysis test: To simulate the photodegradation of leaves after field application of pesticides, the photostability of the sample in solid particle form was further tested. 150 μL of a 3 mg / mL nanoparticle suspension was evenly coated onto a clean glass coverslip and allowed to air dry in the dark. The coverslip with the sample was then irradiated under a 365 nm UV LED lamp, with a vertical distance of 4 cm between the light source and the coverslip. After the set time, the residual sample on the coverslip was dissolved in methanol and sonicated for 2 minutes to fully elute the pesticide. The eluent was filtered through a 0.22 μm filter and then analyzed by HPLC.

[0047] Release performance test: The in vitro release behavior of pyrimethanil and pyrimethanil-ferulic acid cocrystal was determined using the dialysis bag method. Deionized water was used as the release medium. 4 ml of the aqueous suspension of the nano-formulation was transferred to a dialysis bag, which was then placed in a crystallization vessel containing 1 L of water. The system temperature was controlled at 25°C using a constant temperature water bath, and the stirring speed was 50 rpm. At predetermined time intervals, 1 ml of dialysate was collected, and 1 ml of fresh solution was immediately added after sampling to maintain a constant volume. The samples were filtered through a 0.22 μm microporous membrane, and the pyrimethanil content was determined by high-performance liquid chromatography (HPLC). All samples were tested in triplicate.

[0048] Example 1 This embodiment provides a method for preparing pyrimethanil-ferulic acid cocrystal, including: Weigh 2.00 g (approximately 10.0 mmol) of pyrimethanil and 0.97 g (approximately 5.0 mmol, molar ratio 1:0.5), mix thoroughly, and place in the grinding jar of a planetary ball mill (model: QM-3SP04). Then add 20 g of zirconia grinding media with a particle size of 0.2 mm. Prepare 5 mL of an aqueous solution containing 2% (w / v) Atlox 4913 (dispersant) and 2% (w / v) Atlas G-5002L (wetting agent) as the liquid phase medium and add it to the grinding jar. After sealing, grind at 500 rpm for 40 min to obtain a pyrimethanil-ferulic acid nano-eutectic aqueous suspension. After grinding, filter the suspension through a 300-mesh nylon sieve to remove the grinding media. Then, wash the resulting suspension three times with deionized water by centrifugation (10000 rpm, 5 min). Finally, the washed nano-suspension was freeze-dried in a freeze dryer to obtain solid pyrimethanil-ferulic acid eutectic nanoparticles.

[0049] The solid pyrimethanil-ferulic acid eutectic nanoparticles prepared in Example 1 were characterized as follows: (1) X-ray powder diffraction (PXRD): The product obtained in Example 1 was tested using Cu-Kα radiation, and its diffraction pattern is shown below. Figure 1 As shown, the spectrum exhibits characteristic diffraction peaks (error ±0.2°) at 2θ of 8.140°, 8.840°, 10.200°, 12.841°, 14.040°, 15.200°, 16.350°, 17.850°, 18.770°, 19.780°, 20.630°, 21.070°, 22.100°, 25.630°, 26.000°, and 28.480°.

[0050] (2) Single crystal structure analysis: Single crystals of suitable size were obtained by solvent evaporation and analyzed by X-ray single crystal diffraction. The structure is as follows: Figure 2 As shown. The results indicate that this eutectic belongs to the triclinic crystal system, with space group P-. The unit cell parameters are: a = 8.8200 Å, b = 10.7979 Å, c = 17.0715 Å, α = 79.903°, β = 76.930°, γ = 84.617°. The asymmetric unit contains two pyrimethanil molecules and one ferulic acid molecule, confirming a eutectic structure with a molar ratio of 1:0.5.

[0051] (3) Morphology and particle size: The morphology of the product was observed using a scanning electron microscope (SEM), and the results are as follows. Figure 3 As shown, the particles are irregularly shaped lumps. Using ImageJ software, the particle size distribution of over 200 particles was analyzed to obtain a particle size distribution map. Figure 4The average particle size is 573.58 nm, and the distribution ranges from 300 to 700 nm.

[0052] (4) Differential scanning calorimetry: such as Figure 5 As shown, the DSC curves show that the pyrimethanil-ferulic acid eutectic has a single melting point peak with a melting point of 111.67℃, which is higher than that of the pyrimethanil technical grade (approximately 96℃), indicating that the thermal stability is significantly improved after the formation of the eutectic.

[0053] (5) Volatility test: The 12-hour volatilization amount of pyrimethanil technical and the cocrystallization of Example 1 was tested at 75°C. The results are as follows. Figure 6 As shown, the cumulative volatilization rate of pyrimethanil technical grade was 41.96%, while the cumulative volatilization rate of the pyrimethanil-ferulic acid cocrystal was only 7.91%, with a volatilization inhibition rate as high as 81.15%. The results indicate that the cocrystal significantly inhibited the volatilization of the active ingredient.

[0054] (6) Light stability test: Solution photolysis: Pyrimethanil technical grade and the cocrystal from Example 1 were each prepared into 10 mg / L aqueous solutions and irradiated under a 254 nm UV lamp. The degradation curves are shown below. Figure 7 As shown in the figure. After fitting, the photolysis half-life of the original drug was 65.82 h, while the photolysis half-life of the eutectic was extended to 155.44 h, which is 2.36 times that of the original drug.

[0055] Solid-state photolysis: The sample was coated onto a glass slide and irradiated under a 365 nm ultraviolet LED lamp. The degradation curve is shown below. Figure 8 As shown, the solid-state photodegradation half-life of the original drug is 31.19 h, while the half-life of the eutectic is 44.01 h, which is 1.41 times that of the original drug. These results indicate that the eutectic of this invention exhibits excellent resistance to photodegradation in both the liquid and solid phases.

[0056] (7) Release performance test: The in vitro release behavior of pyrimethanil technical and the cocrystal of Example 1 was tested in deionized water using the dialysis bag method. The results are as follows: Figure 9 As shown, the release of pyrimethanil technical grade is relatively slow; however, the pyrimethanil-ferulic acid cocrystal exhibits a significantly faster release rate, rapidly releasing the active ingredient in the early stages. This indicates that the release kinetics of pyrimethanil can be effectively modulated by forming cocrystals, providing a possibility for developing fast-acting formulations.

[0057] Example 2 Weigh pyrimethanil (4.00 g, 20.0 mmol) and ferulic acid (1.94 g, 10.0 mmol, molar ratio 1:0.5), mix thoroughly, and place in the grinding jar of a planetary ball mill. Add 40 g of zirconia grinding beads with a particle size of 0.5 mm. Prepare 10 mL of an aqueous solution containing 3% (w / v) sodium lignosulfonate (dispersant) and 2% (w / v) sodium dodecylbenzenesulfonate (wetting agent) as the liquid phase medium and add it to the grinding jar. After sealing, ball mill at 300 rpm for 90 minutes. After grinding, filter through a 300-mesh nylon sieve to separate the grinding beads and the nano-suspension. Wash the resulting suspension three times with deionized water by centrifugation (10000 rpm, 5 min). Finally, freeze-dry the precipitate in a freeze dryer for 24 hours to obtain solid pyrimethanil-ferulic acid eutectic nanoparticles.

[0058] Product Characterization: PXRD analysis of the obtained product using Cu-Kα radiation showed that its diffraction pattern was consistent with that of Example 1, exhibiting characteristic diffraction peaks (error ±0.2°) at 2θ of 8.140°, 8.820°, 10.200°, 12.850°, 14.060°, 15.200°, 16.450°, 17.840°, 18.780°, 19.800°, 20.620°, 21.030°, 22.070°, 25.620°, 26.029°, and 28.510°, confirming the successful synthesis of the pyrimethanil-ferulic acid eutectic. SEM morphology observation and particle size analysis showed an average particle size of 856.4 nm, within the 10-1000 nm range. DSC analysis showed that the eutectic melting point was 111.2℃, close to that of Example 1. Volatility tests showed a cumulative volatile content of 6.54% over 12 hours, with a volatile inhibition rate of 84.41%. Solution photolysis tests revealed an aqueous half-life of 148.7 h, 2.26 times that of the pyrimethanil technical grade (65.82 h). Solid-state photolysis tests showed a half-life of 42.5 h, 1.36 times that of the technical grade (31.19 h). Release curves indicated that this cocrystal also exhibited a significantly faster release rate than the pyrimethanil technical grade. These results demonstrate that a high-performance pyrimethanil-ferulic acid cocrystal can still be obtained using a lower ball milling speed (300 rpm) and a longer milling time (90 min), although the particle size is slightly larger than in Example 1.

[0059] Example 3 Weigh 1.00 g (5.0 mmol) of pyrimethanil and 0.485 g (2.5 mmol, molar ratio 1:0.5), mix thoroughly, and place in the grinding jar of a planetary ball mill. Add 10 g of zirconia grinding beads with a particle size of 0.1 mm. Prepare 3 mL of an aqueous solution containing 1% (w / v) Atlox 4917 (dispersant) and 1% (w / v) Tween 80 (wetting agent) as the liquid phase medium and add it to the grinding jar. After sealing, ball mill at 600 rpm for 30 minutes. After grinding, filter through a 300-mesh nylon sieve to separate the grinding beads and the nano-suspension. Wash the resulting suspension three times with deionized water by centrifugation (10,000 rpm, 5 min). Finally, place the precipitate in a vacuum drying oven at 40 °C for 36 hours (alternative to freeze drying) to obtain solid pyrimethanil-ferulic acid eutectic nanoparticles.

[0060] Product characterization: The PXRD pattern was completely consistent with that of Example 1, and the positions of the characteristic diffraction peaks matched, proving that the eutectic structure was intact and unchanged by vacuum drying. SEM and particle size analysis showed that the average particle size was 312.5 nm, falling within the preferred range of 300-700 nm. The DSC test showed a melting point of 110.9℃. Volatility performance testing showed that the cumulative volatilization after 12 hours was 7.42%, and the volatilization inhibition rate reached 82.3%, slightly better than Example 1. The half-life of solution photolysis was 160.2 h, which was 2.43 times that of the original drug; the half-life of solid-state photolysis was 45.8 h, which was 1.47 times that of the original drug. The release curve showed a rapid release characteristic. The above results indicate that by using a higher rotation speed (600 rpm) and a shorter time (30 min), not only was a nano-eutectic successfully prepared, but the particle size was also smaller, and some properties were even improved, demonstrating the broad applicability of the method of this invention.

[0061] Example 4 Weigh pyrimethanil (2.00 g, 10.0 mmol) and ferulic acid (0.87 g, 4.5 mmol, molar ratio 1:0.45), mix thoroughly, and place in the grinding jar of a planetary ball mill. Add 40 g of zirconia grinding beads with a particle size of 0.1 mm. Prepare 5 mL of an aqueous solution containing 2% (w / v) Atlox 4913 and 2% (w / v) Atlas G-5002L as the liquid phase medium. To obtain a sample close to the lower limit of the particle size range, a high-energy intermittent grinding process was used: grinding at 600 rpm for 15 minutes, stopping for 5 minutes, and repeating this cycle 6 times (total grinding time 90 minutes). After grinding, filter through a 300-mesh nylon sieve to separate the grinding beads and the nano-suspension. The resulting suspension was washed five times by centrifugation with deionized water (12,000 rpm, 8 min), and the precipitate was finally freeze-dried in a freeze dryer for 48 hours to obtain solid pyrimethanil-ferulic acid eutectic nanoparticles.

[0062] Product Characterization: PXRD testing showed that the product still possessed the characteristic diffraction peaks of the pyrimethanil-ferulic acid co-crystal, but the intensity of some weak peaks was slightly reduced, indicating a slightly lower crystallinity than in Example 1. However, the main characteristic peaks were clearly distinguishable, confirming the formation of the co-crystal. SEM and particle size analysis showed that the average particle size was 98.6 nm, close to the lower limit of the 10-1000 nm range in claim 4, and the particle distribution was relatively uniform. DSC testing showed a melting point of 110.5℃. Volatility testing showed that the cumulative volatilization amount after 12 hours was 10.42%, and the volatilization inhibition rate still reached 75.2%, significantly better than the physical mixture and the original drug. The solution photolysis half-life was 132.5 h, 2.01 times that of the original drug; the solid-state photolysis half-life was 38.9 h, 1.25 times that of the original drug. The release curve still showed a faster release trend than the original drug, and the rate was slightly faster than in Examples 1-3. The above results indicate that even when the particle size is reduced to approximately 100 nm, the eutectic structure can still be maintained, and although the volatilization inhibition and photostability decrease, they are still significantly better than the original drug. Furthermore, more frequent centrifugal washing helps remove excess adjuvants, resulting in a purer product.

[0063] Comparative Example 1 The difference from Example 1 is that pyrimethanil and ferulic acid were gently mixed evenly in a mortar at a molar ratio of 1:0.5, without ball milling.

[0064] Product Characterization: PXRD analysis showed that the product contained characteristic diffraction peaks from both pyrimethanil and ferulic acid, and no eutectic was obtained. SEM and particle size analysis showed a wide particle size distribution, poor particle uniformity, and significant agglomeration. DSC analysis revealed two independent endothermic peaks, corresponding to the melting points of pyrimethanil (97.30℃) and ferulic acid (173.65℃), respectively. Volatility testing showed a cumulative volatilization of 40.58% over 12 hours, comparable to the original drug. Photostability testing showed no significant difference between the product's solution photolysis half-life and solid-state photolysis half-life and the original drug. The release curve was also largely consistent with the original drug.

[0065] The comparison between Example 1 and Comparative Example 1 shows that if the pyrimethanil-ferulic acid eutectic system is prepared by simply mixing with a mortar and pestle without ball milling, the product’s volatility control ability and photochemical stability are not improved, and the drug release curve remains unchanged.

[0066] Comparative Example 2 The difference from Example 1 is that the molar ratio of pyrimethanil to ferulic acid is adjusted to 3:1.

[0067] Product Characterization: PXRD analysis showed that the product contained characteristic diffraction peaks of both pyrimethanil and the pyrimethanil-ferulic acid eutectic. SEM and particle size analysis showed that the particle size was relatively uniform, with an average particle size of 600 nm. DSC analysis showed two independent endothermic peaks, corresponding to the melting point of pyrimethanil (97.26℃) and the melting point of the pyrimethanil-ferulic acid eutectic (111.3℃), respectively. Volatility testing showed a cumulative volatilization of 20.47% over 12 hours. Solution photolysis testing showed an aqueous half-life of 106.4 h, which is 1.62 times that of the pyrimethanil technical grade (65.82 h). Solid-state photolysis testing showed a half-life of 37.74 h, which is 1.21 times that of the technical grade (31.19 h), with the release curve showing a slightly faster release rate than the technical grade.

[0068] The comparison between Example 1 and Comparative Example 2 shows that if the molar ratio of pyrimethanil to ferulic acid is not within the range specified in this application, the final product is a mixture of pyrimethanil and pyrimethanil-ferulic acid eutectic, which will reduce the volatility control ability and photochemical stability.

[0069] Comparative Example 3 The difference from Example 1 is that the molar ratio of pyrimethanil to ferulic acid is adjusted to 1:3.

[0070] Product characterization: PXRD test showed that the characteristic diffraction peaks of the obtained product were significantly different from those of the pyrimethanil-ferulic acid cocrystal of the present invention (Example 1), and the characteristic diffraction peaks of the target cocrystal were not present, indicating that the pyrimethanil-ferulic acid cocrystal of the present invention could not be formed under this molar ratio condition.

[0071] The comparison between Example 1 and Comparative Example 3 shows that if the molar ratio of pyrimethanil to ferulic acid is not within the range specified in this application, the target eutectic product cannot be prepared.

[0072] Comparative Example 4 The difference from Example 1 is that, in the ball milling process, the liquid medium is only deionized water and does not contain dispersants or wetting agents.

[0073] Product Characterization: PXRD analysis showed that while the product exhibited characteristic diffraction peaks of the pyrimethanil-ferulic acid eutectic, the spectra also showed characteristic peaks from both free pyrimethanil and free ferulic acid, indicating incomplete eutectic conversion and a three-phase mixture consisting of the eutectic and the two free raw materials. SEM and particle size analysis revealed the formation of numerous irreversible, dense, hard agglomerates with an average particle size of 4.2 μm, far exceeding the 10-1000 nm nanometer range, exhibiting an extremely wide particle size distribution. DSC analysis showed three independent melting endothermic peaks, corresponding to free ferulic acid, the target eutectic, and free pyrimethanil, respectively. Volatility testing showed a cumulative volatilization rate of 26.75% after 12 hours, with a volatilization inhibition rate of only 36.25%, indicating a significant decrease in volatilization inhibition effect. The half-life of photolysis in solution was 86.3 h, only 1.31 times that of the original drug; the half-life of photolysis in solid state was 34.2 h, only 1.10 times that of the original drug, and the photostability enhancement effect almost disappeared. The release curve did not show rapid dissolution characteristics.

[0074] A comparison of Example 1 and Comparative Example 4 shows that when the liquid medium used in the ball milling process is not the liquid medium of this application, the material is insufficiently wetted, the powder is severely agglomerated, the eutectic synthesis reaction cannot be fully carried out, and the particle size cannot reach the nanoscale. The advantages of the product in inhibiting volatilization, resisting photolysis, and accelerating release are lost, and its overall performance is far inferior to that of the nano-eutectic prepared with added additives.

[0075] The applicant declares that the above description is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope disclosed in the present invention fall within the protection and disclosure scope of the present invention.

Claims

1. A pyrimethanil-ferulic acid eutectic, characterized in that, The pyrimethanil-ferulic acid eutectic is formed by the non-covalent self-assembly of pyrimethanil and ferulic acid in a molar ratio of 1:0.

5.

2. The pyrimethanil-ferulic acid eutectic according to claim 1, characterized in that, The single-crystal structure of the pyrimethanil-ferulic acid eutectic belongs to the triclinic crystal system, with space group P-. The unit cell parameters include: a = 8.8200 Å, b = 10.7979 Å, c = 17.0715 Å, α = 79.903°, β = 76.930°, γ = 84.617°.

3. The pyrimethanil-ferulic acid eutectic according to claim 1, characterized in that, The X-ray powder diffraction pattern of the pyrimethanil-ferulic acid eutectic, measured by Cu-Kα radiation, shows characteristic diffraction peaks at 2θ of 8.140°, 8.840°, 16.350°, 17.850°, and 25.630°, with an error range of ±0.2°.

4. The pyrimethanil-ferulic acid eutectic according to claim 1, characterized in that, The average particle size of the pyrimethanil-ferulic acid eutectic is 10-1000 nm, preferably 300-700 nm.

5. The method for preparing pyrimethanil-ferulic acid eutectic according to any one of claims 1-4, characterized in that, The preparation method includes: Pyrimethanil and ferulic acid were mixed in a molar ratio of 1:(0.45-0.5) and ball-milled to obtain a pyrimethanil-ferulic acid eutectic.

6. The preparation method according to claim 5, characterized in that, The ball milling is carried out in a ball milling medium and a mixed solution; Preferably, the ball milling media comprises zirconium oxide with an average particle size of 0.1-1 mm; Preferably, the mixed solution is an aqueous solution containing a dispersant and a wetting agent; Preferably, the dispersant comprises sodium lignosulfonate, Atlox 4913, Atlox 4917, and Atlox Metasperse 500L, and the mass fraction of the dispersant in the mixed solution is 1%-5%. Preferably, the wetting agent includes sodium dodecylbenzenesulfonate, sodium dodecyl sulfate, Tween 20, Tween 80, and Atlas G-5002L, and the mass fraction of the wetting agent in the mixed solution is 1%-5%.

7. The preparation method according to claim 5, characterized in that, The ball mill used is a planetary ball mill; Preferably, the ball milling rate is 300-600 rpm and the ball milling time is 30-90 min.

8. The preparation method according to claim 5, characterized in that, The preparation method further includes sequentially performing solid-liquid separation, washing, and freeze-drying on the mixture obtained after ball milling; Preferably, the solid-liquid separation method is filtration; Preferably, the cleaning process involves rinsing with deionized water 3-5 times. Preferably, the freeze-drying temperature is -40℃ to -60℃, and the drying time is 24-48h.

9. A pesticide formulation, characterized in that, Includes the pyrimethanil-ferulic acid eutectic as described in any one of claims 1-4.

10. The use of the pyrimethanil-ferulic acid cocrystal according to any one of claims 1-4, or the pesticide formulation according to claim 9, in the prevention and control of agricultural diseases or in the preparation of controlled-release formulations.